Status:
UNKNOWN
Inhaled Ivermectin and COVID-19
Lead Sponsor:
Mansoura University
Conditions:
COVID-19
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Coronavirus disease-19 is global healthcare crisis. Till May 20, 2020, there were approximately 4,789,205 cases and 318,789 related mortalities were identified globally. This dramatic situation led to...
Detailed Description
Coronavirus disease-19 (COVID-19) is a pandemic disease which is caused by the SARS-CoV2 virus. It is one of the biggest single-stranded RNA viruses. SARS-CoV2 Viral polyproteins are responsible for v...
Eligibility Criteria
Inclusion
- Both sexes
- Age above 18
- Test positive for COVID-19 using Reverse transcription polymerase chain reaction (RT-PCR) prior to the start of study.
- Willing to participate in the study
- Mild to moderate severity index according to the WHO criteria
Exclusion
- Hypersensitivity to the study drug.
- History of co-morbid conditions such as: uncontrolled hypertension and diabetes, retinal problems and chronic liver and renal disease.
- Women who are pregnant or breastfeeding.
Key Trial Info
Start Date :
February 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04681053
Start Date
February 25 2021
End Date
December 31 2021
Last Update
February 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura Faculty of Medicine
Al Mansurah, Dakahlyia, Egypt, 35516